With the emergence of other drug classes such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists to treat diabetes and obesity, which also have potential to modulate aging mechanisms [18, 63], there is considerable interest in examining the impact and potential usefulness of these agents on aging hallmarks and measures of healthspan, such as frailty [19, 64]. This evidence concerns the gene GCG and diabetes mellitus.